According to Ying-Wei L. and co-workers (2018), apigenin has anti-tumor effects on triple negative breast cancer cell lines (TNBC) in a dose-dependent manner through (i) a decreased number of migrated cells, (ii) a decreased number of mammospheres in CD44+/CD24− subpopulations, and (iii) the inhibition of transcription factors: yes-associated protein 1 (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ). Here, CD44 is linked to triple-negative breast carcinoma.